The Latest
HUTCHMED Announces SANOVO Trial Demonstrated Significant Progression-Free Survival Benefit Of ORPATHYS® Plus TAGRISSO® In Treatment-Naïve Patients With MET-Overexpressing EGFR-mutated Lung Cancer In China
HUTCHMED announces significant progression-free survival benefits in SANOVO trial combining ORPATHYS® and TAGRISSO® for MET-overexpressing EGFR-mutant lung cancer in China.